International Clinical Trial: A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration

Geneva, Aug. 31 -- International Clinical Trials Registry received information related to the study (NCT07780383) titled 'A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration' on Aug. 19.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Bristol-Myers Squibb

Condition: Alzheimer's Disease Healthy Participants

Intervention: Drug: BMS-986446

Recruitment Status: Not recruiting

Phase: Phase...